Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients: National Health and Nutrition Examination Surveys 1988-2010  by Egan, B.M. et al.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 4 Abstracts 1141was associated with re-establishment of the endothelial lining, suspension of
proteolysis, and reconstitution of a new aortic wall with smooth muscle cells
and extra cellular matrix. ECs exerted their healing properties through para-
crine mechanisms involving up-regulation of endothelium-derived stabi-
lizing factors and recruitment of resident vascular cells. They did not
appear to directly participate in aortic wall repair. Transplantation of
outgrowth ECs (n ¼ seven) reduced by 30% progression of AAAs and
restored abluminal endothelium at 28 days compared with controls (n ¼
nine).
Comment: The authors demonstrate that it is possible using EC seed-
ing techniques to institute recovery of the luminal endothelial lining in an
animal model of AAA. In addition, this new endothelial lining through para-
crine effects appears to result in stabilization of the AAA. It has been previ-
ously known that re-endothelialization of denuded arteries can modulate
the vascular smooth muscle cell phenotype in neointimal hyperplasia. This
study, however, is the ﬁrst to extend this concept to stabilization of
AAAs. It is a unique contribution and perhaps sheds new light on AAA path-
ophysiology and, from the clinical perspective, suggests ultimately a new
mechanism of potentially arresting the growth of AAAs.
Economic Analysis of a Randomized Trial of Percutaneous
Angioplasty, Supervised Exercise or Combined Treatment for
Intermittent Claudication due to Femoropopliteal Arterial Disease
Mazari FAK., Kahn JA., Carradice D., et al. Br J Surg 2013;100:1172-9.
Conclusion: Supervised exercise therapy (SET) is the most cost-effec-
tive ﬁrst-line treatment for intermittent claudication. SET in combination
with percutaneous angioplasty (PTA) is also more cost-effective than PTA
alone.
Summary: This study reports the economic analysis of the authors’
previous study comparing PTA, SET, and combined treatment for intermit-
tent claudication (IC) due to femoropopliteal disease (Mazari FA et al, Br J
Surg 2012;99:39-48). In the original trial, patients with IC secondary to
femoropopliteal disease were randomized to receive PTA, SET, or the
combination of PTA plus SET. Clinical and quality of life indicators were
recorded before therapy and at 1, 3, 6, and 12 months after intervention.
The Short Form-6D health utilities index was calculated from the Short-
Form 36 and plotted. Quality-adjusted life-years (QALYs) were generated
through calculations of the area under the curve. Costs were calculated
using the British National Health Service 2009 to 2010 payment-by-results
tariffs and the National Institute for Health Research Clinical Research
Network Investigation pricing index and adjusted for reinterventions.
Cost per QALY and incremental costs were calculated. A sensitivity analyses
was also performed. A total of 178 patients were randomized (PTA, 60;
SET, 60; PTA+SET, 58). In all treatment groups, there was signiﬁcant
improvement in the SF-6D index (P < .001). There was, however, no
signiﬁcant difference between treatments in mean (95% conﬁdence interval)
QALYs gained (PTA: 0.620 [0.588-0.652]; SET: 0.627 [0.597-0.660];
PTA+SEP: 0.649 [0.622-0.675]). The adjusted mean cost per procedure
was signiﬁcantly higher for PTA (€7301.74) than for SET (€3866.49) and
PTA+SET (€6911.68; P < .001). Costs per QALY were higher for PTA
(€11777.00) compared with SET (€6147.04) and PTA+SET (€10649.74).
This was due to the PTA-alone group undergoing more reinterventions
than the PTA+SET group (nine vs zero reinterventions). QALYs were
lost when PTA alone was used as ﬁrst-line treatment compared with SEP
or PTA+SET. Results were robust and valid in sensitivity analyses.
Comment: On the basis of this analysis, one has to wonder why payers
are willing to pay for percutaneous procedures for treatment of IC but are not
willing to pay for SET for treatment of IC? If one is going to pay for percu-
taneous procedures for treatment of IC, it would seem reasonable to require
that patients treated with percutaneous procedures for IC also be enrolled in
a SET program and that the SET program be paid for as well. The data here
suggest that if one is willing to pay for percutaneous procedures for IC,
requiring SET will actually result in overall decreased costs.
Homocysteine Improves Risk Stratiﬁcation in Patients Undergoing
Endarterectomy for Asymptomatic Internal Carotid Artery Stenosis
Duschek N., Ghai S., Sejkic F., et al. Stroke 2013;44:2311-4.
Conclusion: High plasma homocysteine (Hcy) levels suggest older
patients with asymptomatic carotid stenosis might beneﬁt from intensive
medical therapy rather than from carotid endarterectomy (CEA).
Summary: CEA for asymptomatic patients with high-grade carotid
stenosis (ACAS) has become very controversial. Medical therapy has
advanced, and beneﬁt from CEA for ACAS may be reduced and, some
contend, perhaps eliminated (Abbott AL, Stroke 2009;40:e573-83; and
Spence JD et al, Arch Neurol 2010;67:180-6). The authors of this article
point out that myocardial infarction is responsible for up to 50% ofperioperative deaths after CEA and causes more postoperative deaths than
stroke (Hertzer NR, Arison R. J Vasc Surg 1985;2:661-8). Therefore,
potential candidates for risk stratiﬁcation for carotid surgery include those
with cardiovascular morbidity. A potential candidate for risk stratiﬁcation
is the amino acid Hcy, which is acknowledged as a risk factor for cardiovas-
cular adverse events. In this study, the authors assessed plasma levels of total
Hcy (tHcy) as a biomarker to predict postoperative survival in patients with
ACAS. The study was a prospective, nonrandomized, case series from 2003
to 2012 in which 214 consecutive patients, 130 aged <75 years and 84 aged
$75 years, who underwent CEA for asymptomatic internal carotid artery
stenosis were observed for 8.5 years for occurrence of death after CEA as
the primary end point. Major cardiovascular risk factors and tHcy were
used for computation of prognostic indices. Kaplan-Meier curves were
used to estimate cumulative survival of prognostic indices-based quintiles.
tHcy had a signiﬁcant effect on postoperative survival (P < .0001). tHcy-
based quintiles of prognostic indices showed a better prediction of survival
than age alone. The result was reclassiﬁcation of 17 patients (20.2%) aged
>75 years as ﬁt for surgery but also indicated a high risk for 19 patients
(14.6%) aged <75 years. CEA could not be advised in 79.8% of patients
aged >75 years because of a signiﬁcantly reduced 5-year survival rate.
Comment: In essence, the authors’ data suggest best medical treat-
ment that includes B-vitamins, taking into account folate status, vitamin
B12 status, and renal function, may be a preferred path over CEA in older
hyperhomocysteinemic patients with ACAS. The data, however, lack
a control group of patients with high-grade ACAS who did not undergo
CEA and in whom adverse events were correlated to tHcy levels. As such,
Hcy levels alone are not likely to emerge, based on this study, as a primary
determinant of eligibility for CEA for ACAS. However, the concept that
modifying overall cardiovascular risks in patients with ACAS should be
a concern equal to or greater than neurologic outcome in this patient group
seems quite reasonable.
Blood Pressure and Cholesterol Control in Hypertensive
Hypercholesterolemic Patients: National Health and Nutrition
Examination Surveys 1988-2010
Egan BM., Li J., Qanungo S., et al. Circulation 2013;128:29-41.
Conclusion: There has been signiﬁcant progress in concomitant
hypertension and hypercholesterolemia control. However, signiﬁcant op-
portunities for improvement still remain.
Summary: Most hypertensive patients are also afﬂicted with hypercho-
lesterolemia. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),
lowering low-density lipoprotein cholesterol (LDL-C) from 133 mg/dL at
baseline to 87 mg/dL in hypertensive patients reduced coronary heart
disease 36% compared with placebo-treated patients (Sever PS et al, Lancet
2003;361:1149-58). In the Air Force/Texas Coronary Atherosclerosis
Prevention Study, treatment with lovastatin (20-40 mg/d), compared
with placebo, reduced LDL-C from 156 to 115 mg/dL and reduced coro-
nary heart disease 38% in hypertensive patients (Downs JR, et al, JAMA
1998; 279:1615-22). The National Health and Nutrition Examination
Surveys (NHANES) are used to address compliance issues relevant to control
of cardiovascular disease. In this study, the authors examined concurrent
hypertension and cholesterol control in the NHANES surveys from 1988
to 2010. Speciﬁcally, surveys from 1988 to 1994, 1999 to 2004, and
2005 to 2010 were analyzed. Hypertension was deﬁned by a blood pressure
$140/$90 mm Hg, current medication treatment, and twice-told hyper-
tension status; blood pressure <140/<90 deﬁned control. Hypercholester-
olemia was deﬁned by Adult Treatment Panel (ATP) III criteria based on 10-
year coronary heart disease risk, LDL-C levels, and non-high-density lipo-
protein cholesterol (HDL-C) levels, with values below diagnostic thresholds
deﬁning control. Across surveys, 60.7% to 64.3% of hypertensive patients
were also hypercholesterolemic. From 1988 to 1994 and 2005 to 2010,
control of LDL-C rose 9.2% to 45.4%. Control of concomitant hypertension
and LDL-C rose 5% to 30.7%, and control of combined hypertension and
non-HDL-C cholesterol rose 1.8% to 26.9%. The factors associated with
concomitant hypertension, LDL-C, and non-HDL-C control were statin
use (odds ratio [OR], 10.7), antihypertensive medications (OR, 3.32), age
per 10-year increase (OR, 0.77), two or more health care visits per year
(OR, 1.90), black race (OR, 0.59), Hispanic ethnicity (OR 0.62), cardiovas-
cular disease (OR, 0.44), and diabetes mellitus (OR, 0.54).
Comment: In essence, the data indicate use of statins and hyperten-
sive medications improve blood pressure and cholesterol control in hyper-
tensive hypercholesterolemic patients. This seems obvious, but perhaps
not so obvious is that the percentage of this population achieving control
is increasing over time. What also is not so obvious is that to achieve better
cardiovascular disease control in the United States population, targeting
patients with combined hypertension and hypercholesterolemia who are
also elderly, minorities, or who have diabetes perhaps may be facilitated
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Progression of Carotid Plaque Volume Predicts Cardiovascular Events
Wannarong T., Parraga G., Buchanan D., et al. Stroke 2013;44:1859-65.
Conclusion: To potentially assess response to antiatherosclerotic
therapy, measurement of total plaque volume is superior to both measure-
ment of intima-media thickness (IMT) and total plaque area (TPA).
Summary: Progression of IMT, TPA, and total plaque volume (TPV)
have all been advocated as methods for risk prediction of cardiovascular
events. In this study, the authors report a comparison of progression/
regression of carotid IMT, TPA, and TPV in patients attending vascular
prevention clinics. The goal of the study was to determine which variable
could be best used to assess response to antiatherosclerotic therapy. IMT,
TPA, and TPV were measured at baseline in 349 patients attending vascular
prevention clinics. To qualify for enrollment, a TPA of 40 to 600 mm2 was
required. Follow-up was for#5 years (median, 3.17 years). End points were
vascular death, myocardial infarction, stroke, and transient ischemic attacks.
Follow-up measurements at 1 year were available in 323 patients for IMT
and TPA, and in 306 for TPV. Progression of TPV predicted stroke, death,
or transient ischemic attack (TIA) (Kaplan-Meier log-rank P ¼ .001),
stroke/death/myocardial infarction (MI) (P ¼ .008), and stroke/death/
TIA/MI (any cardiovascular event) (P ¼ .001). Progression of TPA weakly
predicted stroke/death/TIA (P ¼ .097) but not stroke/death/MI (P ¼
.59) or any cardiovascular event (P ¼ .143). IMT also did not predict
stroke/death/MI (P ¼ .13) or any cardiovascular event (P ¼ .455). With
adjustment for coronary risk factors, TPV progression remained a signiﬁcant
predictor (P ¼ .001), but a change in TPA did not. Regression of IMT pre-
dicted events (P ¼ .004).
Comment: The data suggest that TPV at the carotid bifurcation
should be considered as the variable of choice to measure response to anti-
atherosclerotic therapy. Interestingly in this study, regression of IMT rather
than progression predicted events. This may be consistent with the growing
thought that IMT is more representative of hypertensive medial hyper-
trophy and is not truly representative of atherosclerosis (Finn AV et al, Arte-
rioscler Thromb Vasc Biol 2010;30:177-81).
Systematic review and meta-analysis of the early and late outcomes of
open and endovascular repair of abdominal aortic aneurysm
Stather PW., Sidloff D., Dattani N., et al. Br J Surg 2013;100:863-72.
Conclusion: There is no long-term survival beneﬁt for patients who
have endovascular aneurysm repair (EVAR) compared with open repairfor abdominal aortic aneurysm (AAA). There are also signiﬁcantly higher
risks of reintervention and aneurysm rupture after EVAR.
Summary: Several randomized controlled trials have documented
a reduction in 30-day operative mortality and hospital length of stay in
favor of EVAR vs open AAA repair. However, medium-term and long-
term follow-up from the trials varies, with some showing early survival
beneﬁt of EVAR lost over time. Registry data have indicated the need
for close surveillance of endografts, with complications arising in 25% to
40% of patients. The inevitable concern is that long-term durability of
EVAR may be inadequate and that there is a signiﬁcant additional cost
of lifelong surveillance after EVAR (Blackhouse G et al, Value Health
2009;12:245-52). Durability and cost issues may therefore negate the early
survival advantage of EVAR (Rutherford RB, Semin Vasc Surg
2012;25:39-48). The authors sought to perform a systematic review and
meta-analysis to investigate “short-, medium- and long-term outcomes,
including morbidity, reintervention and mortality, associated with EVAR
and open aneurysm repair.” Standard PRISMA (Preferred Reporting Items
for Systematic reviews and Meta-Analyses) guidelines were used for the
preparation of this report (Moher D et al, Int J Surg 2010;8:336-41).
Random-effects Mantel-Haenszel meta-analysis was performed to evaluate
mortality and morbidity outcomes. The data were derived from existing
published randomized trials, and information from Medicare and Swed-
Vasc databases was also included. The result included 25,078 patients
undergoing EVAR and 27,142 undergoing open repair for AAA. The
EVAR patients had signiﬁcantly lower 30-day or in-hospital mortality
(1.3% vs 4.7% for open repair; odds ratio [OR] 0.36; 95% conﬁdence
interval [CI], 0.21-0.61; P < .001). By the 2-year follow-up, there was
no difference in all-cause mortality (14.3% vs 15.2%; OR, 0.87, 95% CI,
0.72-1.06; P ¼ 0.17). This was maintained after at least 4 years of
follow-up (34.7% vs 33.8%; OR, 1.11; 95% CI, 0.91-1.35; P ¼ .30). There
was no signiﬁcant difference in aneurysm-related mortality by follow-up of
2 years or longer. A signiﬁcantly higher proportion of patients undergoing
EVAR required reintervention (P ¼ .003) and suffered aneurysm rupture
(P < .001).
Comment: The debate regarding the overall efﬁcacy of EVAR vs
open repair of AAA continues. EVAR enthusiasts will counter that the
procedure will improve with engineering advances of the devices. Enthusi-
asts for open repair will point out that in many centers, open repair of
infrarenal AAA performed electively has a <4% mortality and that late
rupture after open repair is distinctly unusual. Articles such as this are
academically interesting, but the fact of matter is this genie is long out of
the bottle. There are too many factors driven by physicians, patients, and
industry to change things in the near future. EVAR will continue to be
the preferred method for infrarenal AAA repair unless the procedure is
limited by mandates from public health ofﬁcials and payers.
